Literature DB >> 10952025

Regulatory effect of cytokine production in patients with cerebral infarction by Yulda-Hanso-Tang.

H Y Shin1, H J Jeong, J H Lee, J C Joo, K Y Kim, H J Song, S G Lee, H J Chae, H R Kim, J J Kim, H M Kim.   

Abstract

Yulda-Hanso-Tang (YH-Tang) is a prescription for the Taeumin cerebral infarction (CI) patients according to Sasang constitution philosophy. Taeumin patients with CI were treated with YH-Tang during the acute stage. Clinical signs of CI disappeared markedly in about 2 weeks after oral administration of YH-Tang in all patients. The mean interleukin (IL)-2 serum levels were lower in the patients with CI than in the normal groups, whereas the mean IL-4, IL-6 and IgE levels were significantly higher in the patients. There were no significant differences in interferon-gamma (IFN-gamma) levels between the groups. Serum IFN-gamma and IL-2 levels derived from T helper (Th)1 cells elevated significantly in the patients with CI by YH-Tang administration. Significant reduced serum levels of IL-4 and IL-6 derived from Th2 cells and IgE were observed in the patients treated with YH-Tang. During the period of YH-Tang administration, there were no other adverse effects. The data indicate that YH-Tang has a good CI treatment effect, and that its action may be due to regulation of cytokine production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952025     DOI: 10.3109/08923970009016414

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  2 in total

1.  A new method of diagnosing constitutional types based on vocal and facial features for personalized medicine.

Authors:  Bum Ju Lee; Boncho Ku; Kihyun Park; Keun Ho Kim; Jong Yeol Kim
Journal:  J Biomed Biotechnol       Date:  2012-07-31

2.  Perspective of the human body in sasang constitutional medicine.

Authors:  Junhee Lee; Yongjae Jung; Junghee Yoo; Euiju Lee; Byunghee Koh
Journal:  Evid Based Complement Alternat Med       Date:  2009-09       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.